TGFB1 and metabolic dysfunction-associated steatohepatitis: The bioengineered NMT showed all the hallmarks of NASH (Boeckmans et al., 2018[7]) in terms of alteration in the lipid metabolism-related genes' (CYP2E1, SREBP, and CD36) expression, intracellular lipid accumulation (represented through Oil red and Nile red staining), inflammatory responses (detected by TNF-α, IL-6, and IL-10 genes expression and IL-6 secretion), and fibrosis (evidenced by MMP-2, TGF-β, and COL1A1 genes expression and TGF-β and P3NP secretion).